


or a pharmaceutically acceptable salt thereof

Figure 1A



or a pharmaceutically acceptable salt thereof

Figure 1B

206240 29515001






Figure 1C

200540792925001





Figure 1D




I

or a pharmaceutically acceptable salt thereof
 R_1 and R_3 are the same and are:

2006240 " 499T500F

Figure 1E




I

or pharmaceutically acceptable salt thereof

Figure 1F

2006220" 2907500F



II,

or

I

or pharmaceutically acceptable salt thereof,

Figure 1G










Figure 1H






10113
MnTE-2-PyP



10123
MnTDM-2,5-IP



10143

Figure 1H (continued)










Figure 1H (continued)



Figure 2A

B16 Melanoma tumor - SOD mimetic treatment






Figure 2B






Figure 2C

Effect of Radiation & A EOL 10113 on Mammary Adenocarcinoma




Figure 3

Tumor Growth Inhibition
R3230 AC Mammary Adenocarcinoma in Fisher rats




Figure 4

Tumor growth inhibition (s.q. chambers)

Dose = 6 mg/kg








Figure 5

Tumor Angiogenesis
Dose = 6 mg/kg





Catalytic Antioxidant Metalloporphyrin
[MnTBAP]

Figure 6

Figure 7




Figure 8




Figure 9A




Figure 9B






Figure 10A



Figure 10E



Figure 10B




Figure 10F




Figure 10C



Figure 10G




Figure 10D



Figure 10H

2002707925001



Figure 11




Figure 12






Figure 13A



Group	Hydroxyproline (mg/g wet lung)
Control	~2.1
MnTE-2-PyP	~1.8
Radiation	~7.2
MnTE-2-PyP + Radiation	~5.2

Hydroxyproline
mg/g wet lung

Figure 14




Figure 15





Figure 16

A549 3H-Thymidine uptake at 24 hours



2006240" 29E7500T



Figure 17A

Paraquat-Induced Injury of Human A549 Cells (48 hr)




Figure 17B

Effect of MnTBAP on Paraquat-Induced A549 Cell Injury






Figure 17C

Effect of ZnTBAP on
Paraquat-Induced A549 Cell Injury




Figure 17D

Effect of MnTMPyP on
Paraquat-Induced A549 Cell Injury







Figure 17E

Effect of ZnTMPyP on
Paraquat-Induced A549 Cell Injury



INC-01 Blinded Mucositis Scores




Figure 18

Figure 19
Percentage of Study Days with Ulceration as
Indicated by a Score of 3 or Greater

